Pharmacokinetics comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Dundee becomes the second city in Scotland to introduce a low emission zone. 30 May – Police searching for a father and son missing after hillwalking in Glen Coe confirm they have found two bodies. 31 May – Scotland's UEFA Women's Euro 2025 qualifier match against Israel is delayed after a protestor padlocks himself to the goalposts at Hampden Park. A 24-year-old man is subsequently charged over the incident.
== Gastroenterology == In gastroenterology, the term overlap syndrome may be used to describe autoimmune liver diseases that combine characteristic features of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
General single cell studies including growth Cellular aging: microfluidic devices such as the "mother machine" allow tracking of thousands of individual cells for many generations until they die Microenvironmental control: ranging from mechanical environment to chemical environment Precise spatiotemporal concentration gradients by incorporating multiple chemical inputs to a single device Force measurements of adherent cells or confined chromosomes: objects trapped in a microfluidic device can be directly manipulated using optical tweezers or other force-generating methods Confining cells and exerting controlled forces by coupling with external force-generation methods such as Stokes flow, optical tweezer, or controlled deformation of the PDMS (Polydimethylsiloxane) device Electric field integration Plant on a chip and plant tissue culture Antibiotic resistance: microfluidic devices can be used as heterogeneous environments for microorganisms. In a heterogeneous environment, it is easier for a microorganism to evolve. This can be useful for testing the acceleration of evolution of a microorganism / for testing the development of antibiotic resistance. Viral fusion: these devices also allow the study of the several steps and conditions required for viruses to bind and enter host cells. Information regarding efficiency, kinetics and specific steps of the binding and fusion processes can be obtained using microfluidic flow cells.
Xi's administration enacted a number of changes to the structure of the CCP and state bodies, especially in a large overhaul in 2018. These reforms have been characterized by the integration of CCP and state bodies. Beginning in 2013, the CCP under Xi has created a series of Central Leading Groups: supra-ministerial steering committees, designed to bypass existing institutions when making decisions, and ostensibly make policy-making a more efficient process. Xi was also believed to have diluted the authority of premier Li Keqiang, taking authority over the economy which has generally been considered to be the domain of the premier. February 2014 oversaw the creation of the Central Leading Group for Cybersecurity and Informatization with Xi as its leader. The State Internet Information Office (SIIO), previously under the State Council Information Office (SCIO), was transferred to the central leading group and renamed in English into the Cyberspace Administration of China. As part of managing the financial system, the Financial Stability and Development Committee, a State Council body, was established in 2017. Chaired by vice premier Liu He during its existence, the committee was disestablished by the newly established Central Financial Commission during the 2023 Party and state reforms. Xi has increased the role of the Central Financial and Economic Affairs Commission at the expense of the State Council. 2018 has seen the deepening the reform of the Party and state institutions.
== Utility and benefits == Most countries currently strive to implement eHealth systems for electronic management and communication of healthcare information. The primary drivers for adoption of Electronic Health Records (EHR) and supporting infrastructure include:
Sources: en.wikipedia.org
After protein amino-acid sequences have been translated from nucleic acid chains, they can be edited by appropriate enzymes. This is a form of protein affecting protein sequence, not protein transferring information to nucleic acid.
As the power of the Roman Empire declined, the lands to the south and east of the Mediterranean Sea became incorporated into the Islamic Empires. Some Muslims believe hadiths, such as in Sahih Bukhari, prohibit every intoxicating substance, though the use of any intoxicant or substance is allowed as long as it is for medicinal purposes. Dioscorides' five-volume De Materia Medica, the precursor of pharmacopoeias, remained in use (which was edited and improved in the Arabic versions) from the 1st to 16th centuries, and described opium and the wide range of its uses prevalent in the ancient world.
ErythroMer is a red blood cell substitute in development by KaloCyte, supported with funding by the National Institutes of Health, U.S. Department of Defense, and private investment. Similar to other hemoglobin-based oxygen carriers, the product is stable for several months even when freeze-dried. It can be reconstituted from this lyophilized state in emergencies. This opens up the possibility of eventual stockpiling of ErythroMer, making it easier to supply blood in large amounts to those who need it. The development of this technology was done at Washington University in St. Louis and University of Illinois Urbana-Champaign. Trials have been successful in rats, mice, and rabbits, and human trials are planned. ErythroMer is a reddish blood powder composed of hemoglobin from humans. By coating it with a synthetic polymer, it can sense pH changes, allowing for oxygen pick up in areas where the pH levels are high and disposal where they are low. In the spring of 2024, ErythroMer showed promise in pre-clinical testing. In animal testing, it effectively delivered oxygen and helped revive animals with significant blood loss. In 2025, KaloCyte announced a licensing agreement with Chrysea for ErythroMer production.
It is now known that the underlying physiological correlation for the increase in EPSP size is a postsynaptic upregulation of AMPARs at the membrane, which is accomplished through the interactions of AMPARs with many cellular proteins. The simplest explanation for LTP is as follows (see the long-term potentiation article for a much more detailed account). Glutamate binds to postsynaptic AMPARs and another glutamate receptor, the NMDA receptor (NMDAR). Ligand binding causes the AMPARs to open, and Na+ flows into the postsynaptic cell, resulting in a depolarization. NMDARs, on the other hand, do not open directly because their pores are occluded at resting membrane potential by Mg2+ ions. NMDARs can open only when a depolarization from the AMPAR activation leads to repulsion of the Mg2+ cation out into the extracellular space, allowing the pore to pass current. Unlike AMPARs, however, NMDARs are permeable to both Na+ and Ca2+. The Ca2+ that enters the cell triggers the upregulation of AMPARs to the membrane, which results in a long-lasting increase in EPSP size underlying LTP. The calcium entry also phosphorylates CaMKII, which phosphorylates AMPARs, increasing their single-channel conductance.
Similarly, China permits nationals of non—visa-exempt ASEAN countries to visit Guilin without a visa for a maximum of 6 days if they travel with an approved tour group and enter China from Guilin Liangjiang International Airport. They may not visit other cities within Guangxi or other parts of mainland China. Neither the People's Republic of China nor the Republic of China recognises the passports issued by the other, and neither considers travel between mainland China and areas controlled by the Republic of China as formal international travel. There are arrangements in place for travel between territories controlled by the Republic of China and territories controlled by the People's Republic of China. More generally, authorities in mainland China maintain a system of residency registration known as hukou (Chinese: 户口; lit. 'household individual'), by which government permission is needed to change one's place of residence formally. It is enforced using identity cards. This system of internal border control measures effectively limited internal migration before the 1980s, but subsequent market reforms caused it to collapse as a means of migration control. An estimated 150 to 200 million people are part of the "blind flow" and have unofficially migrated, generally from poor rural areas to wealthy urban areas. However, unofficial residents are often denied official services such as education and medical care and are sometimes subject to both social and political discrimination.
Sources: en.wikipedia.org
Pasteur effect Also Pasteur-Meyerhof effect. A phenomenon observed in facultatively anaerobic cells, including animal tissues and many microorganisms such as yeast, whereby the presence of oxygen in the environment inhibits the cell's use of ethanol fermentation pathways to generate energy, and drives the cell to instead make use of the available oxygen in aerobic respiration; or more generally the observed decrease in the rate of glycolysis or of lactate production in cells exposed to oxygenated air.
in Ohm's law is sufficiently small relative to the other terms that it can be taken to be zero. This occurs in the limit of large magnetic Reynolds numbers, in which magnetic induction dominates magnetic diffusion at the velocity and length scales under consideration. Consequently, processes in ideal MHD that convert magnetic energy into kinetic energy, referred to as ideal processes, cannot generate heat or increase entropy. A fundamental concept underlying ideal MHD is the frozen-in flux theorem, which states that the bulk fluid and the embedded magnetic field are constrained to move together such that one can be said to be "tied" or "frozen" to the other. Therefore, any two points that move with the bulk fluid velocity and lie on the same magnetic field line will continue to lie on that field line even as the points are advected by fluid flows in the system. The connection between the fluid and magnetic field fixes the topology of the magnetic field in the fluid. For example, if a set of magnetic field lines is tied into a knot, then it will remain so as long as the fluid has negligible resistivity. This difficulty in reconnecting magnetic field lines makes it possible to store energy by moving the fluid or the source of the magnetic field. The energy can then become available if the conditions for ideal MHD break down, allowing magnetic reconnection to release the stored energy from the magnetic field.
This may be determined by systematically substituting oxygen's stable isotope 18O into the various molecules that participate in the reaction and checking for the isotope in the product. The chemical mechanism can also be elucidated by examining the kinetics and isotope effects under different pH conditions, by altering the metal ions or other bound cofactors, by site-directed mutagenesis of conserved amino acid residues, or by studying the behaviour of the enzyme in the presence of analogues of the substrate(s).
Gas chromatography–vacuum ultraviolet spectroscopy (GC-VUV) is a universal detection technique for gas chromatography. VUV detection provides both qualitative and quantitative spectral information for most gas phase compounds. GC-VUV spectral data is three-dimensional (time, absorbance, wavelength) and specific to chemical structure. Nearly all compounds absorb in the vacuum ultraviolet region of the electromagnetic spectrum with the exception of carrier gases hydrogen, helium, and argon. The high energy, short wavelength VUV photons probe electronic transitions in almost all chemical bonds including ground state to excited state. The result is spectral "fingerprints" that are specific to individual compound structure and can be readily identified by the VUV library. Unique VUV spectra enable closely related compounds such as structural isomers to be clearly differentiated. VUV detectors complement mass spectrometry, which struggles with characterizing constitutional isomers and compounds with low mass quantitation ions. VUV spectra can also be used to deconvolve analyte co-elution, resulting in an accurate quantitative representation of individual analyte contribution to the original response. This characteristically lends itself to significantly reducing GC runtimes through flow rate-enhanced chromatographic compression. VUV spectroscopy follows the simple linear relationship between absorbance and concentration described by the Beer–Lambert Law, resulting in more accurate retention time-based identification.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.